A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome

References

• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.9058730
   PubMed Web of Science ®Google Scholar
• Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Hematol. 2012;91(9):1333–1343. doi:10.1007/s00277-012-1472-822547053
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–2964. doi:10.1182/blood-2013-03-49288423980065
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440. doi:10.1200/JCO.2002.04.11712011120
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-819230772
   PubMed Web of Science ®Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117(12):2697–2702. doi:10.1002/cncr.2577421656747
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–1152. doi:10.1038/leu.2011.7121494260
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712. doi:10.1182/blood-2014-06-58280925224413
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009;106(39):16811–16816. doi:10.1073/pnas.090710910619805378
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764–2773. doi:10.1182/blood-2009-02-20354719546476
   PubMed Web of Science ®Google Scholar
• Grovdal M, Karimi M, Tobiasson M, et al. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation. Leukemia. 2014;28(2):411–413. doi:10.1038/leu.2013.26524025691
   PubMed Web of Science ®Google Scholar
• Nannya Y, Takeda J, Sato S, et al. Molecular signatures that predict response to azacitidine treatment for myelodysplastic syndromes. Blood. 2017;130:4182.
   Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627, quiz 3699. doi:10.1182/blood-2013-08-51888624030381
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87. doi:10.1038/leu.2013.26924045501
   PubMed Web of Science ®Google Scholar
• Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017;8(63):106948–106961. doi:10.18632/oncotarget.2215729291002
   PubMedGoogle Scholar
• Umezu T, Ohyashiki K, Ohyashiki JH. Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy. Anal Biochem. 2011;415(2):145–150. doi:10.1016/j.ab.2011.04.03521600184
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425. doi:10.1182/blood-2005-10-414916609072
   PubMed Web of Science ®Google Scholar
• Itoh Y, Kuratsuji T, Aizawa S, Sai M, Ohyashiki K, Toyama K. Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. Ann Hematol. 1991;63(5):270–275.1659916
   PubMed Web of Science ®Google Scholar
• Azuma K, Umezu T, Imanishi S, et al. Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing. Leuk Res. 2017;62:23–28. doi:10.1016/j.leukres.2017.09.00828964959
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89–92.6185846
   PubMed Web of Science ®Google Scholar
• Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21(35):5427–5440. doi:10.1038/sj.onc.120560012154405
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315–1325. doi:10.1182/blood-2008-06-16324618832655
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–613. doi:10.1200/JCO.2009.23.478120038729
   PubMed Web of Science ®Google Scholar
• Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH. Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. Biochem Pharmacol. 2014;89(3):361–369. doi:10.1016/j.bcp.2014.03.00824680865
   PubMed Web of Science ®Google Scholar
• Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH. Chromatin regulation by HP1γ contributes to survival of 5-azacytidine-resistant cells. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.01166
   PubMed Web of Science ®Google Scholar
• Karimi M, Johansson S, Ekstrom TJ. Using LUMA: a Luminometric-based assay for global DNA-methylation. Epigenetics. 2006;1(1):45–48.17998810
   PubMed Web of Science ®Google Scholar
• Rauch TA, Pfeifer GP. The MIRA method for DNA methylation analysis. Methods Mol Biol. 2009;507:65–75. doi:10.1007/978-1-59745-522-0_618987807
   PubMedGoogle Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32(12):1242–1248. doi:10.1200/JCO.2013.50.310224663049
   PubMed Web of Science ®Google Scholar
• Komashko VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics. 2010;5(3):229–240.20305384
   PubMed Web of Science ®Google Scholar